Navigation Links
Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
Date:6/2/2009

Bionovo at a very fitting moment, when my experience, technical knowledge and regulatory understanding can greatly contribute to the company's success. I believe Menerba is a groundbreaking product that will provide a safer treatment for women suffering from menopausal symptoms, and I look forward to contributing to its successful development."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may ca
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
2. Bionovo Announces 2008 Highlights and Year-End Financial Results
3. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
4. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
5. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
6. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
7. Bionovo to Present at the Piper Jaffray Healthcare Conference
8. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Reports Third Quarter 2008 Financial Results
10. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
11. Bionovo to Present at Canaccord Adams Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... Pa. , July 30, 2015  Discovery ... that it has received the second $1.0M tranche ... Innovation Research (SBIR) grant valued at up to ... company,s aerosolized KL4 surfactant as a potential medical ... injury.  Discovery Labs was awarded an initial $1.0 ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ ... for continuous operation up to 1500 bar. The sanitary design gauge of the ... toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for the ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Pioneer ... , ... February 4, 2010 -- An integrated approach to plant breeding, product positioning and agronomic ... sustainably increasing agricultural productivity, William S. Niebur , vice president – DuPont Crop ...
... Mass. , Feb. 4 Interleukin Genetics, Inc. (NYSE Amex: ... at the 2010 BIO CEO & Investor Conference. The 12th Annual BIO ... the Waldorf-Astoria in New York . , Interleukin Genetics Chief Executive ... Company and discuss recent milestones at 1:00 p.m. ET in ...
... , Research Superiority ... Hub at Texas Center for Superconductivity (TcSUH-ARH) , HOUSTON ... has received a Research Superiority Award from the Texas Emerging ... on behalf of the ETF board. The University of Houston ...
Cached Biology Technology:DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production 2Interleukin Genetics to Present at the 12th Annual BIO CEO Conference 2UH Superconductivity Center Receives Texas Emerging Technology Fund Award 2UH Superconductivity Center Receives Texas Emerging Technology Fund Award 3UH Superconductivity Center Receives Texas Emerging Technology Fund Award 4UH Superconductivity Center Receives Texas Emerging Technology Fund Award 5UH Superconductivity Center Receives Texas Emerging Technology Fund Award 6UH Superconductivity Center Receives Texas Emerging Technology Fund Award 7
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... stimulating the frontal cortex in adults, researchers have shown that ... people's actions. , It has been known for over ... the left frontal cortex, he or she often suffers difficulties ... language impairments, it has been difficult for researchers to test ...
... infections resistant to antibiotics, previously only associated with ... are now widespread in the community and coming ... University School of Medicine and Grady Memorial Hospital, ... Internal Medicine, reports on a dramatic rise in ...
... 68,000 infants published in this week's New England Journal ... can safely prevent 98 percent of severe cases of ... hospital visits and 500,000 pediatric deaths each year worldwide. ... trials ever conducted worldwide, research championed by an Eastern ...
Cached Biology News:Study indicates dramatic rise in antibiotic-resistant community-acquired staph infections 2Study indicates dramatic rise in antibiotic-resistant community-acquired staph infections 3New vaccine for condition that kills 500,000 children a year 2New vaccine for condition that kills 500,000 children a year 3
Request Info...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Request Info...
Services include subcloning into an expression vector. Tagged protein will be expressed in small scale for testing yield and solubility and then in 1L culture for large scale affinity purification. E...
Biology Products: